Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo.

Standard

Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. / Yuan, J; Krämer, A; Matthess, Y; Yan, R; Spänkuch, B; Gätje, R; Knecht, Rainald; Kaufmann, M; Strebhardt, K.

in: ONCOGENE, Jahrgang 25, Nr. 12, 12, 2006, S. 1753-1762.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Yuan, J, Krämer, A, Matthess, Y, Yan, R, Spänkuch, B, Gätje, R, Knecht, R, Kaufmann, M & Strebhardt, K 2006, 'Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo.', ONCOGENE, Jg. 25, Nr. 12, 12, S. 1753-1762. <http://www.ncbi.nlm.nih.gov/pubmed/16278675?dopt=Citation>

APA

Yuan, J., Krämer, A., Matthess, Y., Yan, R., Spänkuch, B., Gätje, R., Knecht, R., Kaufmann, M., & Strebhardt, K. (2006). Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. ONCOGENE, 25(12), 1753-1762. [12]. http://www.ncbi.nlm.nih.gov/pubmed/16278675?dopt=Citation

Vancouver

Yuan J, Krämer A, Matthess Y, Yan R, Spänkuch B, Gätje R et al. Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. ONCOGENE. 2006;25(12):1753-1762. 12.

Bibtex

@article{6066815fe112478ca6d0ee0d491713b8,
title = "Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo.",
abstract = "Cyclin B1 is the regulatory subunit of cyclin-dependent kinase 1 (Cdk1) and is critical for the initiation of mitosis. Accumulating data indicate that the deregulation of cyclin B1 is tightly linked to neoplastic transformation. To study the phenotype and the potential preclinical relevance, we generated HeLa cell lines stably transfected with the plasmids encompassing short hairpin RNA (shRNA) targeting cyclin B1. We demonstrate that the reduction of cyclin B1 caused inhibition of proliferation by arresting cells in G2 phase and by inducing apoptosis. Cells, entering mitosis, were impaired in chromosome condensation and alignment. Importantly, HeLa cells with reduced cyclin B1 were more susceptible to the treatment of small interfering RNA targeting Polo-like kinase 1 (Plk1) and to the administration of the chemotherapeutic agent taxol. Finally, HeLa cells with reduced cyclin B1 showed inhibited tumor growth in nude mice compared to that of control cells. In summary, our data indicate that cyclin B1 is an essential molecule for tumor cell survival and aggressive proliferation, suggesting that the downregulation of cyclin B1, especially in combination with other molecular targets, might become an interesting strategy for antitumor intervention.",
author = "J Yuan and A Kr{\"a}mer and Y Matthess and R Yan and B Sp{\"a}nkuch and R G{\"a}tje and Rainald Knecht and M Kaufmann and K Strebhardt",
year = "2006",
language = "Deutsch",
volume = "25",
pages = "1753--1762",
journal = "ONCOGENE",
issn = "0950-9232",
publisher = "NATURE PUBLISHING GROUP",
number = "12",

}

RIS

TY - JOUR

T1 - Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo.

AU - Yuan, J

AU - Krämer, A

AU - Matthess, Y

AU - Yan, R

AU - Spänkuch, B

AU - Gätje, R

AU - Knecht, Rainald

AU - Kaufmann, M

AU - Strebhardt, K

PY - 2006

Y1 - 2006

N2 - Cyclin B1 is the regulatory subunit of cyclin-dependent kinase 1 (Cdk1) and is critical for the initiation of mitosis. Accumulating data indicate that the deregulation of cyclin B1 is tightly linked to neoplastic transformation. To study the phenotype and the potential preclinical relevance, we generated HeLa cell lines stably transfected with the plasmids encompassing short hairpin RNA (shRNA) targeting cyclin B1. We demonstrate that the reduction of cyclin B1 caused inhibition of proliferation by arresting cells in G2 phase and by inducing apoptosis. Cells, entering mitosis, were impaired in chromosome condensation and alignment. Importantly, HeLa cells with reduced cyclin B1 were more susceptible to the treatment of small interfering RNA targeting Polo-like kinase 1 (Plk1) and to the administration of the chemotherapeutic agent taxol. Finally, HeLa cells with reduced cyclin B1 showed inhibited tumor growth in nude mice compared to that of control cells. In summary, our data indicate that cyclin B1 is an essential molecule for tumor cell survival and aggressive proliferation, suggesting that the downregulation of cyclin B1, especially in combination with other molecular targets, might become an interesting strategy for antitumor intervention.

AB - Cyclin B1 is the regulatory subunit of cyclin-dependent kinase 1 (Cdk1) and is critical for the initiation of mitosis. Accumulating data indicate that the deregulation of cyclin B1 is tightly linked to neoplastic transformation. To study the phenotype and the potential preclinical relevance, we generated HeLa cell lines stably transfected with the plasmids encompassing short hairpin RNA (shRNA) targeting cyclin B1. We demonstrate that the reduction of cyclin B1 caused inhibition of proliferation by arresting cells in G2 phase and by inducing apoptosis. Cells, entering mitosis, were impaired in chromosome condensation and alignment. Importantly, HeLa cells with reduced cyclin B1 were more susceptible to the treatment of small interfering RNA targeting Polo-like kinase 1 (Plk1) and to the administration of the chemotherapeutic agent taxol. Finally, HeLa cells with reduced cyclin B1 showed inhibited tumor growth in nude mice compared to that of control cells. In summary, our data indicate that cyclin B1 is an essential molecule for tumor cell survival and aggressive proliferation, suggesting that the downregulation of cyclin B1, especially in combination with other molecular targets, might become an interesting strategy for antitumor intervention.

M3 - SCORING: Zeitschriftenaufsatz

VL - 25

SP - 1753

EP - 1762

JO - ONCOGENE

JF - ONCOGENE

SN - 0950-9232

IS - 12

M1 - 12

ER -